Table 3-2.

Cause of death by cumulative response within 1 year in age 45–64

Age 45–64	All N= 222	CCyR* N= 202	MMR* N=169	MR4·5* N=75	CMR N=40
Number of death, No. (%)	19 (9)	12 (6)	7 (4)	3 (2)	0
Progression to AP/BP, No. (%)	5 (26)	3 (25)	1 (14)	0	0
SCT complications, No. (%)	2 (11)	0	0	0	0
Secondary malignancy, No. (%)	4 (21)	3 (25)	2 (29)	1 (33)	0
Cardiovascular events, No. (%)	1 (5)	1 (8)	1 (14)	0	0
Sepsis, No. (%)	1 (5)	1 (8)	0	0	0
Dementia, No. (%)	1 (5)	1 (8)	1 (14)	1 (33)	0
Surgical complications, No. (%)	1 (5)	1 (8)	1 (14)	0	0
HCV cirrhosis, No. (%)	1 (5)	0	0	0	0
Unknown, No. (%)	3 (16)	2 (17)	1 (14)	1 (33)	0
Type of TKI, No. (%)
Imatinib	15 (79)	10 (83)	6 (86)	3 (100)	0
Dasatinib	1 (5)	1 (8)	1 (14)	0	0
Nilotinib	3 (16)	1 (8)	0	0	0
Overall cumulative response, No. (%)
CCyR	14 (74)	12 (100)	7 (100)	3 (100)	0
MMR	11 (58)	9 (75)	7 (100)	3 (100)	0
MR4·5	5 (26)	4 (33)	3 (43)	3 (100)	0
CMR	3 (16)	2 (17)	1 (14)	1 (33)	0
Disease status** at the time of death, No. (%)
CML-AP/BP	5 (26)	3 (25)	1 (14)	0	0
CML-CP	1 (5)	1 (8)	0	0	0
CCyR	1 (5)	1 (8)	1 (14)	0	0
MMR	3 (16)	3 (25)	2 (29)	0	0
MR4·5	2 (11)	2 (17)	2 (29)	2 (67)	0
CMR	5 (26)	1 (8)	0	0	0
Unknown	2 (11)	1 (8)	1 (14)	1 (33)	0

^*CCyR includes CCyR or better; MMR includes MMR or better; MR4·5 includes MR4·5 or better.

^**Each status represents the best category of response or disease status at the time of death.

Abbreviations: AP, accelerated phase; BP, blast phase; CP, chronic phase; CCyR, complete cytogenetic response; MMR, major molecular response; MR4·5, molecular response by a 4·5 log reduction on the international scale; CMR, complete molecular response; SCT, stem cell transplant; TKI, tyrosine kinase inhibitor; CML, chronic myeloid leukemia; HCV, hepatitis C virus.